Diagnosis and treatment guidelines for aberrant portal hemodynamics: The Aberrant Portal Hemodynamics Study Group supported by the Ministry of Health, Labor and Welfare of Japan

Working Subgroup for Clinical Practice Guideline for Aberrant Portal Hemodynamics *,**

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Idiopathic portal hypertension (IPH), causing aberrant portal hemodynamics, is a disease with an as yet unidentified cause and no established treatment protocol. The Japanese research group on IPH in Japan was set up in 1975 by the Ministry of Health, Labor and Welfare. Extrahepatic portal obstruction and Budd–Chiari syndrome (BCS) have since been added to the group's research subjects. The aims of the research group are to accurately evaluate the current status of the three diseases in Japan, elucidate their etiology and pathogenesis, and develop new treatments. Due to the long-term efforts of the Japanese research group, aberrant portal hemodynamics has been investigated in a variety of aspects, from epidemiological and pathological studies to molecular biology analyses. As a result, it has been shown that there are abnormal genes in the liver, specific for IPH. In addition, pathological findings of BCS were internationally compared and the difference in findings between Japan and Europe (or North America) has been clarified. Furthermore, it was found that complication rates of hepatocellular carcinoma in BCS were higher in Japan. Based on the research, “Diagnosis and treatment of aberrant portal hemodynamics (2001)”, including diagnostic criteria for aberrant portal hemodynamics, was published in 2001. In 2013, it was revised to “Diagnosis and treatment guidelines for aberrant portal hemodynamics (2013)” after the incorporation of diagnosis and treatment in accordance with its current status.

Original languageEnglish
Pages (from-to)373-386
Number of pages14
JournalHepatology Research
Volume47
Issue number5
DOIs
Publication statusPublished - Apr 2017

Fingerprint

Japan
Hemodynamics
Guidelines
Health
Research
Research Subjects
Therapeutics
Clinical Protocols
North America
Epidemiologic Studies
Molecular Biology
Hepatocellular Carcinoma
Liver
Genes
Banti's syndrome

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Infectious Diseases

Cite this

Diagnosis and treatment guidelines for aberrant portal hemodynamics : The Aberrant Portal Hemodynamics Study Group supported by the Ministry of Health, Labor and Welfare of Japan. / Working Subgroup for Clinical Practice Guideline for Aberrant Portal Hemodynamics *,**.

In: Hepatology Research, Vol. 47, No. 5, 04.2017, p. 373-386.

Research output: Contribution to journalArticle

Working Subgroup for Clinical Practice Guideline for Aberrant Portal Hemodynamics *,**. / Diagnosis and treatment guidelines for aberrant portal hemodynamics : The Aberrant Portal Hemodynamics Study Group supported by the Ministry of Health, Labor and Welfare of Japan. In: Hepatology Research. 2017 ; Vol. 47, No. 5. pp. 373-386.
@article{dccb7a266b564c58a36f928617941c3d,
title = "Diagnosis and treatment guidelines for aberrant portal hemodynamics: The Aberrant Portal Hemodynamics Study Group supported by the Ministry of Health, Labor and Welfare of Japan",
abstract = "Idiopathic portal hypertension (IPH), causing aberrant portal hemodynamics, is a disease with an as yet unidentified cause and no established treatment protocol. The Japanese research group on IPH in Japan was set up in 1975 by the Ministry of Health, Labor and Welfare. Extrahepatic portal obstruction and Budd–Chiari syndrome (BCS) have since been added to the group's research subjects. The aims of the research group are to accurately evaluate the current status of the three diseases in Japan, elucidate their etiology and pathogenesis, and develop new treatments. Due to the long-term efforts of the Japanese research group, aberrant portal hemodynamics has been investigated in a variety of aspects, from epidemiological and pathological studies to molecular biology analyses. As a result, it has been shown that there are abnormal genes in the liver, specific for IPH. In addition, pathological findings of BCS were internationally compared and the difference in findings between Japan and Europe (or North America) has been clarified. Furthermore, it was found that complication rates of hepatocellular carcinoma in BCS were higher in Japan. Based on the research, “Diagnosis and treatment of aberrant portal hemodynamics (2001)”, including diagnostic criteria for aberrant portal hemodynamics, was published in 2001. In 2013, it was revised to “Diagnosis and treatment guidelines for aberrant portal hemodynamics (2013)” after the incorporation of diagnosis and treatment in accordance with its current status.",
author = "{Working Subgroup for Clinical Practice Guideline for Aberrant Portal Hemodynamics *,**} and Fuminori Moriyasu and Yoshihiro Furuichi and Atsushi Tanaka and Hajime Takikawa and Hiroshi Yoshida and Isao Sakaida and Katsutoshi Obara and Makoto Hashizume and Masayoshi Kage and Satoko Ohfuji and Seigo Kitano and Seiji Kawasaki and Shigehiro Kokubu and Shoichi Matsutani and Susumu Eguchi and Susumu Shiomi and Tetsuhito Kojima and Yoshihiko Maehara and Yukio Kuniyoshi",
year = "2017",
month = "4",
doi = "10.1111/hepr.12862",
language = "English",
volume = "47",
pages = "373--386",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Diagnosis and treatment guidelines for aberrant portal hemodynamics

T2 - The Aberrant Portal Hemodynamics Study Group supported by the Ministry of Health, Labor and Welfare of Japan

AU - Working Subgroup for Clinical Practice Guideline for Aberrant Portal Hemodynamics ,

AU - Moriyasu, Fuminori

AU - Furuichi, Yoshihiro

AU - Tanaka, Atsushi

AU - Takikawa, Hajime

AU - Yoshida, Hiroshi

AU - Sakaida, Isao

AU - Obara, Katsutoshi

AU - Hashizume, Makoto

AU - Kage, Masayoshi

AU - Ohfuji, Satoko

AU - Kitano, Seigo

AU - Kawasaki, Seiji

AU - Kokubu, Shigehiro

AU - Matsutani, Shoichi

AU - Eguchi, Susumu

AU - Shiomi, Susumu

AU - Kojima, Tetsuhito

AU - Maehara, Yoshihiko

AU - Kuniyoshi, Yukio

PY - 2017/4

Y1 - 2017/4

N2 - Idiopathic portal hypertension (IPH), causing aberrant portal hemodynamics, is a disease with an as yet unidentified cause and no established treatment protocol. The Japanese research group on IPH in Japan was set up in 1975 by the Ministry of Health, Labor and Welfare. Extrahepatic portal obstruction and Budd–Chiari syndrome (BCS) have since been added to the group's research subjects. The aims of the research group are to accurately evaluate the current status of the three diseases in Japan, elucidate their etiology and pathogenesis, and develop new treatments. Due to the long-term efforts of the Japanese research group, aberrant portal hemodynamics has been investigated in a variety of aspects, from epidemiological and pathological studies to molecular biology analyses. As a result, it has been shown that there are abnormal genes in the liver, specific for IPH. In addition, pathological findings of BCS were internationally compared and the difference in findings between Japan and Europe (or North America) has been clarified. Furthermore, it was found that complication rates of hepatocellular carcinoma in BCS were higher in Japan. Based on the research, “Diagnosis and treatment of aberrant portal hemodynamics (2001)”, including diagnostic criteria for aberrant portal hemodynamics, was published in 2001. In 2013, it was revised to “Diagnosis and treatment guidelines for aberrant portal hemodynamics (2013)” after the incorporation of diagnosis and treatment in accordance with its current status.

AB - Idiopathic portal hypertension (IPH), causing aberrant portal hemodynamics, is a disease with an as yet unidentified cause and no established treatment protocol. The Japanese research group on IPH in Japan was set up in 1975 by the Ministry of Health, Labor and Welfare. Extrahepatic portal obstruction and Budd–Chiari syndrome (BCS) have since been added to the group's research subjects. The aims of the research group are to accurately evaluate the current status of the three diseases in Japan, elucidate their etiology and pathogenesis, and develop new treatments. Due to the long-term efforts of the Japanese research group, aberrant portal hemodynamics has been investigated in a variety of aspects, from epidemiological and pathological studies to molecular biology analyses. As a result, it has been shown that there are abnormal genes in the liver, specific for IPH. In addition, pathological findings of BCS were internationally compared and the difference in findings between Japan and Europe (or North America) has been clarified. Furthermore, it was found that complication rates of hepatocellular carcinoma in BCS were higher in Japan. Based on the research, “Diagnosis and treatment of aberrant portal hemodynamics (2001)”, including diagnostic criteria for aberrant portal hemodynamics, was published in 2001. In 2013, it was revised to “Diagnosis and treatment guidelines for aberrant portal hemodynamics (2013)” after the incorporation of diagnosis and treatment in accordance with its current status.

UR - http://www.scopus.com/inward/record.url?scp=85013422714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013422714&partnerID=8YFLogxK

U2 - 10.1111/hepr.12862

DO - 10.1111/hepr.12862

M3 - Article

AN - SCOPUS:85013422714

VL - 47

SP - 373

EP - 386

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - 5

ER -